바실루스 코아굴란스 그림

8 동료 심사 연구의 그림

전체 생강 아연 이눌린 커큐민 락타아제 베르베린 차전자피 비피도박테리움 롱검 비피도박테리움 락티스 비피도박테리움 비피덤 사카로마이세스 보울라디 락토바실루스 가세리 락토바실루스 플란타룸 락토바실루스 애시도필루스 부티레이트(나트륨/칼슘 부티레이트) 페퍼민트 오일 바실루스 코아굴란스 췌장효소(판크렐리파아제) 알로에 베라(내엽 젤) 알파-갈락토시다아제 소 초유 오메가-3 지방산(EPA/DHA) 비타민 A 비타민 D 프럭토올리고당(FOS) 갈락토올리고당(GOS) L-글루타민 중쇄중성지방(MCT 오일) N-아세틸시스테인(NAC)

All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other

Figure 2 Chart

Total IBS symptom scores decrease significantly in the Bacillus coagulans LBSC group compared to placebo over the treatment period. Both bloating and abdominal pain subscores show improvement.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 3 Chart

Individual IBS symptom domains including bloating, abdominal pain, urgency, and incomplete evacuation are tracked across study visits. Bacillus coagulans supplementation shows benefits across multiple symptom dimensions.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 3. Change in stool consistency from baseline (visit 2/d 1) to end of treatment (visit 4/d 80) in Test-G and Placebo-H. The Bristol stool form scale is used to assess the stool consistency as reported by total number of subjects.

Figure 4 Chart

Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 4. Clustering of multivariate data using principal component analysis analysis of responses for different variables of quality of life from Test-G (G) and Placebo-H (H) arms at end of treatment (visit 04). Variables considered are— abdominal pain,

Figure 5 Chart

Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions.

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A …

Figure 1. The ﬂowchart of study protocol.

Figure 6 Chart

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or …

Figure 2. The effect of probiotic intervention on clinical improvement assessed by IBS-SSS scores (a–f). * indicates a statistically signiﬁcant improvement (p < 0.05) between both the groups given probiotic intervention and the placebo group in the tot

Figure 7 Chart

Probiotic intervention outcomes assessed by IBS Severity Scoring System (IBS-SSS) in a three-arm clinical trial. Both Bifidobacterium lactis BI040 and Bacillus coagulans BC300 groups showed statistically significant improvement in total IBS-SSS scores compared to placebo.

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or …

Figure 8 Chart

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or …

Figure 9 Chart

Supplementary outcome data from the randomized trial evaluating single-strain probiotics for irritable bowel syndrome, comparing gastrointestinal symptom improvements across treatment arms.

The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or …